This article discusses Antitope’s developed highly sensitive ex vivo T cell assay technology that can detect T cell responses against T cell epitopes in therapeutic proteins. These assays can be used to select non-immunogenic lead proteins as well as support the optimisation of leads by engineering out T cell epitopes